{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:46:21Z","timestamp":1761489981890},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12941-016-0140-6","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T03:57:58Z","timestamp":1460606278000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin"],"prefix":"10.1186","volume":"15","author":[{"given":"Abrar K.","family":"Thabit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Jahangir","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Khaleduzzaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin W.","family":"Garey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,12]]},"reference":[{"issue":"7316","key":"140_CR1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nature09397","volume":"467","author":"SA Kuehne","year":"2010","unstructured":"Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature. 2010;467(7316):711\u20133.","journal-title":"Nature"},{"issue":"1","key":"140_CR2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4161\/gmic.1.1.10768","volume":"1","author":"GP Carter","year":"2010","unstructured":"Carter GP, Rood JI, Lyras D. The role of toxin A and toxin B in Clostridium difficile-associated disease: past and present perspectives. Gut Microbes. 2010;1(1):58\u201364.","journal-title":"Gut Microbes"},{"issue":"9491","key":"140_CR3","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(05)67420-X","volume":"366","author":"M Warny","year":"2005","unstructured":"Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366(9491):1079\u201384.","journal-title":"Lancet"},{"issue":"2","key":"140_CR4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1128\/CMR.18.2.247-263.2005","volume":"18","author":"DE Voth","year":"2005","unstructured":"Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev. 2005;18(2):247\u201363.","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"140_CR5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1128\/JCM.44.2.353-358.2006","volume":"44","author":"T \u00c5kerlund","year":"2006","unstructured":"\u00c5kerlund T, Svenungsson B, Lagergren A, Burman LG. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol. 2006;44(2):353\u20138.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"140_CR6","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/dks450","volume":"68","author":"F Babakhani","year":"2013","unstructured":"Babakhani F, Bouillaut L, Sears P, Sims C, Gomez A, Sonenshein AL. Fidaxomicin inhibits toxin production in Clostridium difficile. J Antimicrob Chemother. 2013;68(3):515\u201322.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"140_CR7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1017\/ice.2015.270","volume":"37","author":"ST Housman","year":"2016","unstructured":"Housman ST, Thabit AK, Kuti JL, Quintiliani R, Nicolau DP. Assessment of Clostridium difficile burden in patients over yime with first episode infection following fidaxomicin or vancomycin. Infect Control Hosp Epidemiol. 2016;37(2):215\u20138.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"11","key":"140_CR8","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1469-0691.2008.02092.x","volume":"14","author":"S Persson","year":"2008","unstructured":"Persson S, Torpdahl M, Olsen KE. New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA\/cdtB) genes applied to a Danish strain collection. Clin Microbiol Infect. 2008;14(11):1057\u201364.","journal-title":"Clin Microbiol Infect"},{"key":"140_CR9","first-page":"1","volume":"8","author":"AK Thabit","year":"2015","unstructured":"Thabit AK, Nicolau DP. Lack of correlation between bristol stool scale and quantitative bacterial load in Clostridium difficile infection. Infectious Dis: Res Treat. 2015;8:1\u20134.","journal-title":"Infectious Dis: Res Treat"},{"issue":"9","key":"140_CR10","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365529709011203","volume":"32","author":"SJ Lewis","year":"1997","unstructured":"Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920\u20134.","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"140_CR11","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","volume":"31","author":"SH Cohen","year":"2010","unstructured":"Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431\u201355.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"Suppl 2","key":"140_CR12","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1093\/cid\/cis338","volume":"55","author":"TJ Louie","year":"2012","unstructured":"Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, Krulicki W. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis. 2012;55(Suppl 2):S132\u201342.","journal-title":"Clin Infect Dis"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-016-0140-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T06:55:43Z","timestamp":1498287343000},"score":1,"resource":{"primary":{"URL":"http:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-016-0140-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,12]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["140"],"URL":"https:\/\/doi.org\/10.1186\/s12941-016-0140-6","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,12]]},"article-number":"22"}}